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The prognosis of ovarian cancers remains poor as approximately
two-thirds of the patients have already suffered from stage III or
IV disease at the time of diagnosis. Ovarian cancers initially grow
locally and invade the capsule. The cancer cells then exfoliate into
the peritoneal cavity and disseminate. The patients often have
massive ascites involving various kinds of growth factors,
suggesting the potential involvement of growth factors in ascites
in the progression and dissemination of ovarian cancers.
Activation of the signalling pathways mediated by growth factors
may contribute to the unrestricted growth that is characteristic of
these tumours. Growth factors are also able to stimulate changes 
in cellular morphology, motility and invasiveness, which may
promote both the metastasis and dissemination of tumour cells.
Among these growth factors, hepatocyte growth factor (HGF),
independently identified as scatter factor, is known to have mito-
genic, motogenic and morphogenic actions on a variety of epithe-
lial and endothelial cell types that express its receptor (HGFR)
(Stoker et al, 1987; Montesano et al, 1991; Lamszus et al, 1998).
The HGF-HGFR system is considered to be a principal paracrine
mediator of normal mesenchymal–epithelial interactions (Rosen et
al, 1994), and has been also shown to be involved in the formation
and spreading of tumours (Jeffer et al, 1996a; Nakamura et al,
1997). HGFR is a 190 kDa heterodimer composed of a 50 kDa
extracellular a-subunit and a 145 kDa b-subunit. These subunits
are synthesized as a single-chain precursor, pro-HGFR. The 
b-subunit contains the extracellular ligand binding domain, trans-
membrane domain and intracellular tyrosine kinase domain.
Ligand binding to HGFR induces dimerization of adjacent
receptor molecules and autophosphorylation in its C-termini. The
HGFR tyrosine kinase functions through a Src homology 2 (SH2)
docking site that can activate several signalling pathways
(Ponzetto et al, 1994; Pellici et al, 1995). The pathway involved in
the response to HGF has been tentatively described as follows: the
first phase of the response (motogenesis), which results from
cytoskeletal reorganization, loss of intercellular junctions and cell
migration, is mainly dependent on phosphatidylinositol 3-kinase
(PI3-kinase) and Rac activation; the second phase (mitogenesis)
requires stimulation of the Ras-MAP kinase (MAPK) cascade; 
the third phase (morphogenesis) is dependent on the signal
transducers and activators of the transcription (STAT) pathway
(Boccacino et al, 1998).
There is evidence that changes in the HGF-HGFR system are
involved in the development or progression of ovarian cancers.
HGFR is expressed in the normal ovarian surface epithelium and
various types of primary ovarian cancers (Di Renzo et al, 1994;
Moghul et al, 1994). Marked overexpression of HGFR protein
occurs in some fractions of ovarian cancers, as determined by
Western blotting (Di Renzo et al, 1994; Corps et al, 1997). This
suggests that ovarian cancers progress and metastasize to the
surrounding tissues through activation of the HGF-HGFR system.
HGF activates Ras protein by shifting the equilibrium toward
the guanosine 5¢-triphosphate (GTP)-bound state and increases 
the uptake of guanine nucleotides of Ras (Hartmann et al, 1994;
Ridley et al, 1995). We are interested in the Ras-MAPK cascade
downstream of HGFR since mutated forms of the human ras genes
have been detected in a fraction of ovarian cancers (Teneriello et
al, 1993). The contribution of this abberant Ras function to mutant
Ras-positive tumours remains to be determined, while it is clear
that ovarian cancer development can occur in the absence of muta-
tions in ras genes. An investigation of physiologically controlled
Ras-MAPK signalling in response to HGF would help to deter-
mine the role of the abberant Ras function in cancer development.
To clarify the role of Ras activation by HGF, we collected a panel
of human ovarian cancer cell lines that were able to transmit the
HGF-mediated stimuli to MAPK protein through HGFR autophos-
phorylation. These cells overexpressed HGFR protein and carried
the wild-type sequences of the K-, H- and N-ras genes. The
motility was enhanced by HGF treatment in ovarian cancer cells
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chemoattraction and the resultant invasiveness. The H-Ras Y57, a
dominant-negative Ras protein, abrogated the stimulation of cell
migration and invasiveness of the ovarian cancer cells in response
to HGF, suggesting that the Ras-MAPK cascade is essential for the
motogenic activity of ovarian cancer cells. In addition, the MAPK
and the PI3-kinase pathways downstream of Ras are involved in
the invasiveness of the cells.
MATERIALS AND METHODS
Cells and cell culture
Eight human ovarian cancer cell lines were used in the present
study. We obtained KF and MH cells from Dr Toshihiro Kikuchi,
National Defense Medical College; MCAS, TYK-nu, Kuramochi,
and PA-1 cells from the Health Science Research Resources Bank
(HSRRB); HAC-2 cells from Dr Masato Nishida, Tsukuba
University; SKOV-3 cells from Dr Hiroaki Kobayashi, Kyushu
University. All cell lines were maintained in RPMI medium (Gibco)
supplemented with 10% fetal calf serum (FCS; Medical Link).
Measurement of HGF in culture media
Cells were incubated to confluency in RPMI with 10% FCS, then
the medium was replaced with serum-free medium followed by 
a further incubation for 48 h at 37°C. HGF in the medium was
determined by the enzyme-linked immunosorbent assay (ELISA)
(IMMUNIS EIA kit, Tokushumeneki Kenkyusho, Japan)
according to the manufacturer’s instructions.
Western blotting to determine HGFR expression
HGF receptor expression was analysed by Western blotting.
Subconfluent cells were lysed with ice-cold lysis buffer (sodium
chloride (NaCl) 100 mM, Tris–HCl pH 7.8, 20 mM, sodium fluo-
ride (NaF) 50 mM, NP-40 1%, glycerol 10%, sodium orthovana-
date 1 mM, phenylmethylsulphonyl fluoride 1.25 mM, leupeptin
10 mg ml–1, aprotinin 10 mg ml–1), and centrifuged at 13 000 g for
10 min at 4°C to remove debris. The protein concentration was
determined using a Coomassie Protein Assay (PIERCE) and 
100 mg of each protein was resolved by 10% sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto a nitrocellulose membrane in a semi-dry transfer
cell (Bio Rad). The blots were incubated with the anti-c-Met
monoclonal antibody, C-28 (Santa Cruz Biotechnology, Inc),
followed by incubation with horseradish peroxidase-linked anti-
rabbit antibodies (Amersham), and analysed with ECL system
(Amersham).
Analysis of phosphorylated c-Met
Subconfluent cells were incubated with serum-free medium 
over night and 100 ng ml–1 of HGF was added for 10 min. 
The cells were lysed on ice in PY buffer (Tris–HCl pH 7.8 20 mM,
NaCl 50 mM, NaF 50 mM, Na4P2O7 30 mM, EGTA 5 mM, Triton 
X-100 1%, sodium orthovanadate 1 mM) containing freshly 
added protease inhibitors (phenylmethylsulphonyl fluoride 1 mM,
leupeptin, 1 mg ml–1, aprotinin 10 mg ml–1) (Pelicci et al, 1995).
One milligram of each lysate was incubated with agarose
conjugated anti-c-Met antibody, C-28 (Santa Cruz Biotechnology,
Inc.) over night at 4°C. Immunocomplexes were washed with 
the same buffer twice, resuspended in SDS boiling buffer and
resolved by 10% SDS-PAGE. The separated proteins were blotted
onto nitrocellulose membranes and the membranes were incubated 
with the anti-phosphotyrosine antibody, PY99 (Santa Cruz
Biotechnology, Inc), followed by incubation with horseradish
peroxidase-linked anti-mouse antibodies (Amersham), and
analysed with ECL system (Amersham).
Screening for ras mutation
Total RNA from the cells was isolated using ISOGEN (Nippon
Gene). One microgram of total RNA was reverse transcribed into
cDNA by reverse transcriptase (Perkin-Elmer) and selective
amplification of the K-, H- and N-ras gene sequence was
performed using the polymerase chain reaction (PCR). Amplified
DNA fragments were dot-blotted onto a nylon membrane
(Hybond-N+, Amersham) and denatured in 0.4 N sodium
hydroxide (NaOH). The membrane was pre-hybridized for 1 h at
42°C in hybridization solution (Rapid-hyb buffer, Amersham).
Hybridization was performed for 2 h at 42°C in the same solution
with 10 pmol 32P-labelled mutation-specific oligonucleotide
probes surrounding codon 12, 13 and 61 of K-, H- and N-ras
(Takara). After hybridization, the membrane was washed twice in
1 ´ SSC (saline-sodium citrate), 0.1% SDS at room temperature
for 10 min, and in 0.1 ´ SSC, 0.1% SDS at 50°C for 20 min. The
membrane was exposed to the plate of a Bio-image analyser
(BAS1000, FUJIX, Japan). Point mutations were confirmed by
sequencing (Takara Taq Cycle Sequencing Kit, Takara) according
to the manufacturer’s instructions.
Analysis of MAPK activity
Subconfluent cells were incubated with serum-free RPMI for 48 h
and 10 ng ml–1 of HGF was added for 15 min. Cells were lysed
with lysis buffer (Tris–HCl pH 8.0 20 mM, Triton X-100 1%,
glycerol 10%, NaCl 137 mM, magnesium chloride 1.5 mM, EGTA
1m M, NaF 50 mM, sodium orthovanadate 1 mM) containing
freshly added protease inhibitors (phenylmethylsulphonyl fluoride
1m M, leupeptin 1 mg ml–1, aprotinin 10 mg ml–1). After centrifuga-
tion at 13 000 g for 10 min to remove debris, 100 mg of the
proteins was separated by 12.5% SDS-PAGE and the separated
proteins were transferred to nitrocellulose membranes. The
membranes were incubated with the MAPK monoclonal antibody,
Ab-1 (CalBiochem) or phospho-specific MAPK antibody, pTEpY
(Promega) followed by incubation with 125I-labelled antibody
(Amersham). The amount of each protein was quantitated using a
Bio-image analyser (BAS1000, FUJIX, Japan).
Boyden chamber assay
Cell motility was determined using Boyden chambers with 8-mm
pore size polycarbonate filters (Coster). NIH3T3 cell-conditioned
medium was placed in the lower compartment of the Boyden
chambers as a source of chemoattractant. Cells were trypsinized,
and 5 ´ 104 cells were suspended in 100 ml of RPMI containing
0.1% bovine serum albumin (BSA) and placed in the upper
compartment. For the motility assay, 1 or 10 ng ml–1 of HGF was
added to the lower compartment. For checkerboard analysis, 1 or
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ment. The cells were incubated for 10 h at 37°C, fixed with
methanol, and then stained with haematoxylin and eosin. Cells on
the upper surface of the filter were removed with a cotton swab,
and cells that had migrated to the lower surface were counted
under a light microscope at 200 ´ magnification. Six fields were
counted for each assay and compared to the control.
The invasion assay was performed essentially according to the
method reported previously (Kobayashi et al, 1994). The filter was
coated with 20 mg of Matrigel (Becton Dickinson Collaborative
Research, Bedford, MA, USA), which is a mixture of basement
membrane components such as fibronectin, type IV collagen,
laminin, vitronectin and proteoglycans. The cells were trypsinized,
and 1 ´ 105 cells were suspended in 100 ml RPMI containing 0.1%
BSA and placed in the upper compartment. NIH3T3 cell-condi-
tioned medium was placed in the lower compartment and incu-
bated for 24 h at 37°C, after which 10 ng ml–1 of HGF was added
into upper and lower compartments. The subsequent procedures
were the same as those of the cell motility assay.
In order to examine whether NIH3T3 cells conditioned medium
effects on human Met, Boyden chamber assay was performed with
the addition of 500 ng ml–1 anti-human HGF antibody, H0652
(SIGMA) into both compartments of the chamber. The same
concentration of goat IgG, sc-2028 (Santa Cruz) was used as a
control study.
Adenovirus-mediated gene transfer of dominant
negative Ras
A recombinant adenovirus, AdexCAHRasY57, expressing a domi-
nant-negative Ras was generated by cloning the human H-ras
cDNA, with asparatic acid to tyrosine substitution at amino acid
position 57 (Ueno et al, 1997). We also used a control adenovirus,
AdLacZ in which lacZ was driven by the SRa promotor and the
lacZ expression was evaluated by histostaining.
Co-infection of the cells with adenoviral vectors was carried out
by incubating subconfluent cells with vectors in phosphate buffer
saline (PBS) for 2 h at room temparature. The cells were then
washed with PBS twice and the medium was changed for RPMI
containing 10% FCS. The cells were incubated at 37°C until each
assay as described.
For the analysis of cell growth, after 24 h of infection, cells were
plated at 1 ´ 104 cells per 2.0 mm 24-well plates in RPMI supple-
mented with 10% FCS and incubated for 24 h. Viable cells were
counted and compared to the control.
For the motility and invasion assays, 5 ´ 104 cells and 1 ´ 105
cells, respectively, were plated in a Boyden chamber after 24 h of
infection and the Boyden chamber assay was performed as
described above.
For the detection of MAPK activity, subconfluent cells were
infected with the adenoviral vectors. After 24 h, the medium was
replaced with serum-free RPMI for 48 h and 10 ng ml–1 HGF was
added for 15 min. Cells were lysed and MAPK activity was deter-
mined as described above.
Effect of PD98059 and LY294002 on motility and
invasiveness
We used PD98059 and LY294002 as specific inhibitors of MAP
kinase kinase (MEK) and PI3-kinase respectively. After 24 h
incubation with serum-free medium, subconfluent Kuramochi
cells were treated either with 10 mM PD98059 (Cal Biochem) or 
50 mM LY294002 (Cal Biochem) dissolved in dimethyl sulphoxide
(DMSO). After an additional 24 h incubation, 10 ng ml–1 of HGF
was added to the culture medium for 15 min, and the cells were
lysed. MAP kinase activity was determined for PD98059-treated
Kuramochi cells as described above. Proteins (100 mg) from
LY294002-treated Kuramochi cells were separated by 10% 
SDS-PAGE and transferred to nitrocellulose membranes. Each
membrane was incubated with the phospho-Akt antibody (Ser473)
(New England Biolabs. Inc), followed by incubation with 125I-
labelled antibody (Amersham). The amount of protein was quanti-
fied using a Bio-image analyser (BAS1000, Fujix).
For the Boyden chamber assay, Kuramochi cells were plated
onto the upper chamber. Either 10 mM PD98059 or 50 mM
LY249002 was put in both compartments of the chamber. We used
the same concentration of DMSO as a control.
RESULTS
HGF-mediated signalling cascade in ovarian cancer
cells
In the present study, we examined the role of the Ras-mediated
signalling cascade in regulating the potent motogenic activity of
HGF in ovarian cancer cells. Thus, we addressed whether the
panel of eight ovarian cancer cell lines used here maintained the
response to exogenous HGF and HGF-mediated signal trans-
duction. First, we examined the cell lines for production of HGF
into the culture media by the ELISA method to exclude the
possible autocrine-growth factor pathway. Detectable levels of
HGF were absent in the conditioned media from these eight
ovarian cancer cell lines, thereby providing no evidence for HGF-
HGFR autocrine activity (data not shown).
We determined the relative levels of HGFR expression by
Western blotting analysis using a polyclonal anti-peptide antibody
directed against the COOH-terminus of the human HGFR (C-28).
As shown in Figure 1, high levels of 145 kDa HGFR protein, along
with variable levels of its unprocessed precursor (170 kDa) were
detected in six cell lines (HAC-2, SKOV-3, Kuramochi, MH, 
KF and MCAS). Lower but still detectable levels of HGFR 
were observed in the remaining PA-1 and TYK-nu cells. These
observations were in agreement with previous reports of over-
expression of HGFR protein in ovarian cancers, across multiple
types of tumours, even though the expression level showed
substantial variation between tumours (Di Renzo et al, 1994).
Binding of HGFR to its ligand induces autophosphorylation at
tyrosine residues and initiates a cascade of intracellular events. To
test whether the HGFR overexpressed in these cell lines was
tyrosine-phosphorylated in response to HGF, cell lysates were
immunoprecipitated with an anti-HGFR antibody (C-28) and
immunoblotted with an anti-phosphotyrosine antibody (Figure
2A). HGFR of each cell line was phosphorylated in response to
HGF.
We next evaluated the status of ras gene mutations in the panel
of cell lines. Dot blot hybridization with mutation-specific
oligomers was used to screen for mis-sense mutations at codons
12, 13 and 61 of the K-, H- and N-ras genes and further direct
sequence analysis was performed on PCR-amplified DNA isolated
from each of the cell lines. Two cell lines had a ras gene mutation
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Figure 2 (A) Tyrosine phosphorylation of HGF receptor. Subconfluent cells were incubated with serum-free RPMI for 24 h and 100 ng ml–1 of HGF was added
for 10 min. Protein extracted by non-ionic detergent in the presence of kinase and phosphatase inhibitors was immunoprecipitated with agarose-conjugated
anti-c-Met antibody, separated under reducing conditions, blotted onto nitrocellulose membranes, and probed with anti-phosphotyrosine monoclonal antibody,
followed by incubation with horseradish peroxidase-linked anti-rabbit antibodies, and analysed with ECL system. HGF receptor of each cell-line was
phosphorylated in response to HGF. The arrow indicates the p145 b-chain of HGF receptor. (B) Activation of MAPK by HGF stimulation. Subconfluent cells were
incubated with serum-free RPMI for 
48 hours and 10 ng ml–1 of HGF was added for 15 min. Cell extracts were electrophoresed in polyacrylamide gels and transferred onto nitrocellulose
membranes. The blots were incubated with anti-MAPK monoclonal antibody (Ab-1), followed by incubation with 125l-goat anti-mouse antibody. The upper band
of the doublet appearing at 42 kDa represents a hyperphosphorylated form of p42 MAPK. The blots were also incubated with anti-phospho-specific MAPK
antibody (pTEpY), followed by incubation with 125l-goat anti-rabbit antibody. HGF treatment activated MAPK in each cell line
HGF
p42(Ab—1)
(—)
SKOV—3 Kuramochi HAC—2
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TYK—nu KF MH
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Figure 1 Western blotting analysis of the HGF receptor. One hundred micrograms of proteins obtained by lysis of each ovarian cancer cell line were analysed.
Blots were incubated with monoclonal antibodies the COOH terminal tail of the HGF receptor, which labelled the p145 b-chain and the p170 precursor of the Mr
190 000 receptor, followed by incubation with horseradish peroxidase linked anti-rabbit antibodies (Amersham), and were analysed with ECL system
(Amersham). MAPK was shown as an internal control in the lower panel. The arrows indicated the p170 precursor form and p145 b-chain of HGF receptor and
p42 MAPK respectivelyinvolving a single base substitution at codon 12 of K-ras, changing
a glycine to valine in MCAS, and at N-ras codon 12 causing
substitution of aspartic acid for glycine in PA-1. Thus, we
excluded these two cell lines from further analysis. No mutations
were detected at codon 12, 13 or 61 of the K-, H- or N-ras genes in
the remaining six cancer cell lines.
There is considerable evidence that Ras proteins are critical
relay switches that control signalling pathways connecting the cell
surface with the nucleus. Activated GTP-bound Ras has the poten-
tial to phosphorylate and activate a cascade of serine/threonine
kinases. Thus, we investigated the alterations in MAPK activity in
response to HGF (Figure 2B). Migration of the active form of
MAPK was slower than that of the inactive MAPK form, resulting
in an electrophoretic mobility shift of the 42 kDa protein. HGF
treatment resulted in a marked increase in the level of active
MAPK in ovarian cancer cell lines. This was supported by the
definite signal reaction with phospho-specific MAPK antibody. In
contrast, inactive, unphosphorylated MAPK was predominant in
the absence of HGF. Our results indicated that HGF caused HGFR
phosphorylation and MAPK activation.
HGF-stimulated motogenic and invasive activity of
ovarian cancer cells
Next, we examined the effects of HGF on the motogenic activity
of the panel of six ovarian cancer cell lines (Figure 3). The cells
which migrated to the lower surface of the filter were counted after
10 h incubation. We used the conditioned medium from NIH3T3
cells to stimulate the basal level of motogenic activity of the cells.
To address whether the promotion of motogenic activity is specific
to human HGF, we investigated the alteration in motility and inva-
siveness of Kuramochi cells in the presence or the absence of 
500 ng ml–1 anti-human HGF antibody. Basal levels of motility
and invasiveness were not affected by the anti-HGF antibody treat-
ment in Kuramochi cells (Figure 3 and Table 1). The antibody-
treated Kuramochi cells stimulated with HGF corresponded to the
suppression of cell migration and invasiveness to the constitutive
level, whereas the antibody-non-treated Kuramochi cells
responded to HGF and markedly enhanced their motility and inva-
siveness. Thus, the data demonstrated the specific human HGF
effect on the cell motility and invasiveness of ovarian cancer cells.
The motility of four cell lines (Kuramochi, MH, TYK-nu and
KF) was enhanced 6–16 times by treatment with HGF in a dose-
dependent manner. However, the promotion of cell motility was
unremarkable in SKOV-3 and HAC-2 cells, which showed rela-
tively high constitutive motility. To determine whether the
HGF and ovarian carcinoma cell invasion 895
British Journal of Cancer (2000) 82(4), 891–899 © 2000 Cancer Research Campaign
Figure 3 Cell motility of ovarian cancer cells. A total of 1 ng ml–1 or 
10 ng ml–1 of HGF was added into the lower compartments of the Boyden
chambers. Migrated cells were determined as described in Materials and
Methods. Values are means ± s.d. from triplicate determinations. Number of
control represent numbers of migrated cells in the absence of HGF, and the
bars represent the relative ratio to the control. The motility of each cell line
was enhanced by treatment with HGF. Kuramochi + anti-HGF represents the
data with 500 ng ml–1 of anti-HGF antibody in both upper and lower
compartments of the chambers. Addition of anti-HGF antibody abrogated
HGF induced cell motility
Table 1 Invasion assay
Cell line HAC-2 SKOV-3 Kuramochi MH TYK-nu KF Kuramochi
+anti-HGF
Invaded HGF (–) 217 ± 42 1424 ± 301 134 ± 71 200 ± 81 808 ± 85 452 ± 83 163 ± 18
cells/6HPF HGF(+) 195 ± 30 2309 ± 110 678 ± 188 670 ± 126 1503 ± 113 999 ± 223 204 ± 29
Activation of 0.90 1.62 5.06 3.35 1.86 1.99 1.25
invasion (fold)
Cells which migrated to the lower surface of the Matrigel-coated filter in the Boyden chamber were counted after 24-h incubation. Kuramochi+anti-HGF
represents the data with 500 ng ml–1 of anti-HGF antibody in both upper and lower chambers. Values are means ± s.d. from triplicate determinations.
Table 2 Checkerboard analysis of Kuramochi cells
Upper chamber
0 ng ml–1 1 ng ml–1 10 ng ml–1
Lower chamber 0 ng ml–1 69 ± 10 226 ± 57 90 ± 36
1 ng ml–1 196 ± 100 333 ± 64 405 ± 96
10 ng ml–1 404 ± 65 583 ± 46 665 ± 106
Various concentrations of HGF were added into the upper and/or lower
compartments. The cells which migrated to the lower surface of the filter of
the Boyden chamber were counted after 10-h incubation. Values are 
means ± s.d. from triplicate determinations.
20
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Number
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HAC—2
353.9 343.7 63.5 43.4 26.6 5.8 73.7
SKOV—3 Kuramochi MH TYK—nu KF Kuramochi
+anti—HGF
control
HGF 1ng/ml
HGF 10ng/mlmotogenic stimulation by HGF was due to either enhanced chemo-
kinetic or chemotactic activity, we performed the checkerboard
assay repeatedly using Kuramochi cells that were sensitive to HGF
(Table 2). A larger effect was obtained when HGF was added 
into the lower compartment only, indicating that HGF exerted 
a dose-dependent chemotactic effect. Addition of HGF 
(10 ng ml–1) to both compartments induced a 9.6-fold stimulation
of migration compared with the value obtained without addition of
HGF. These results presumably represented the general response
of cell motility induced by HGF.
The responsiveness of the cell lines was further examined by the
invasion assay in which the cells were plated on Matrigel-coated
filters for 24 h (Table 1). In this assay, SKOV-3 cells showed a
higher basal level of invasiveness compared with the other cells. In
the presence of HGF, the invasive activity was augumented in five
of six cell lines; 1.62-fold in SKOV-3, 5.06-fold in Kuramochi,
3.35-fold in MH, 1.86-fold in TYK-nu, and 1.99-fold in KF. HAC-
2 cells showed no increase in invasive activity in response to HGF.
These observations were still compatible with the notion that HGF
mediated the motogenic signal through its receptor, although there
were cell type-specific variations in migration and invasiveness.
Regulation of HGF-mediated stimulation by the 
Ras-dependent signalling
The present study demonstrated a positive correlation between
MAPK activation induced by HGF and enhanced cell migration
and the resultant increase in invasiveness in the ovarian cancer cell
lines. To determine directly whether the Ras-dependent signalling
pathway is required for cancer cell migration and invasiveness, we
infected the four ovarian cancer cell lines, SKOV-3, Kuramochi,
MH and KF, with the recombinant adenovirus AdexCAHRasY57
expressing the dominant-negative Ras Y57 mutant protein. This
mutant protein has been shown to interfere with the function of
endogenous Ras (Ueno et al, 1997). We determined the infec-
tion efficiency by co-infecting with AdexCAHRasY57 and
AdCALacZ. After 72-h incubation of co-infection, the percentage
of cells stained positively for b-galactosidase was counted. The
percentages of positively stained cells were 99.2% in SKOV-3,
99.4% in KF, 97.0% in MH and 95.8% in Kuramochi cells respec-
tively.
The Ras-MAPK cascade plays an important role in cell prolifer-
ation. Therefore, we analysed the influence of dominant-negative
Ras Y57 mutant protein on cell growth. Cell death was unde-
tectable within the 120-h incubation following infection of these
four ovarian cancer cell lines with AdexCAHRasY57. As
expected, Ras Y57 interfered with growth of the four ovarian
cancer cells. The relative cell number at the end of the 120-h incu-
bation period of the infected ovarian cancer cells ranged from
21.6% to 56.8%, as compared with uninfected cell cultures.
However, cell growth suppression due to Ras Y57 expression was
undetectable following 24-h incubation after infection. The rela-
tive cell number of infected/uninfected cells was 96.9% in SKOV-
3, 86.7% in Kuramochi, 97.6% in MH and 98.8% in KF. Thus, the
effects of dominant-negative Ras Y57 on the motility and inva-
siveness of four ovarian cancer cell lines was evaluated with
observation periods of 10 h and 24 h respectively.
Ras Y57 completely abrogated MAPK activation in response to
HGF in these four ovarian cancer cell lines, which was demon-
strated by using the infected cells incubated for 48 h with serum-
free media followed by HGF stimulation for 15 min (Figure 4). We
thus tested whether the extinction of HGF-stimulated MAPK acti-
vation resulted in suppression of ovarian cancer cell migration
(Table 3). Twenty-four hours after AdexCAHRasY57 infection, 
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Figure 4 Effects of dominant-negative Ras on the phosphorylation of p42 MAPK. Western blotting analysis of four cell lines infected with AdexCAHRasY57.
Twenty-four hours after transfection with the adenoviral vector, the medium was replaced with serum-free RPMI for 48 h and 10 ng ml–1 HGF was added for 15
min. Cells were lysed and MAPK activation was determined with anti-MAPK monoclonal antibody (Ab-1) and anti-phospho-specific MAPK antibody (pTEpY).
Activation of MAPK by HGF treatment was suppressed in all ovarian cancer cell lines expressing the dominant-negative Ras (ras DN). The lower lanes show
cells infected with AdCALacZ virus (control). The arrows indicate p42 MAPK of which the activation is shown by a band shift (Ab-1) or reaction with pTEpY5 ´ 104 cells were plated in the upper compartment of Boyden
chambers. The number of cells which migrated to the lower
surface was counted after 10 h incubation. The HGF-stimulated
cell migration was most clearly inhibited in KF cells following
AdexCAHRasY57 infection (Table 3). Ras Y57-expressed KF
cells stimulated with HGF corresponded to the suppression of cell
migration to the constitutive level. These results indicated that
HGF acted on cell motility through a Ras-dependent pathway in
KF cells. In turn, partial suppression of HGF-stimulated cell
migration was observed in SKOV-3 (55.7%), Kuramochi (54.4%)
and MH (60.2%) cells. Thus, it is possibile that the motogenic
response of ovarian cancer cells to HGF involves Ras-mediated
signal transduction but its importance is dependent on the cell
type.
We then examined the alterations in invasiveness of the ovarian
cancer cells following infection with AdexCAHRasY57 (Table 4).
Twenty-four hours after infection, 1 ´ 105 cells were plated in
Boyden chambers. The potential of HGF to stimulate invasive
activity in response to HGF was completely abrogated in all of the
ovarian cancer cells infected with AdexCAHRasY57.
Regulation of HGF-mediated responses by downstream
effectors of Ras
It is now evident that the altered responses of ovarian cancer cells
brought about by HGF-mediated signalling are Ras-dependent,
and the events occurring downstream of this protein are the subject
of investigation. Ras activates a number of signalling pathways
through its ability to activate key effector proteins. The most
extensively studied of these are the MAP kinase pathway and the
PI3-kinase pathway (Webb et al, 1998; Potempa et al, 1998). Thus,
we evaluated the involvement of these pathways in the motogenic
activity of ovation cancer cells. We used PD098059 as a MEK
inhibitor and LY294002 as a PI3-kinase inhibitor, respectively, to
abrogate signal transduction through each pathway. First of all, we
examined the effect of each inhibitor (10 mM PD098059 and 50 mM
LY294002) on Kuramochi cell growth as signal transduction
through the MAPK and the PI3-kinase cascades is involved in cell
proliferation. However, a 24 h treatment of Kuramochi cells either
with PD098059 or LY294002 did not result in cell growth inhibi-
tion, compared with the DMSO-treated control cells (data not
shown).
HGF treatment resulted in a marked increase in the level of
active Akt protein that was a downstream effector of PI3-kinase,
and phosphorylated MAPK in the absence of inhibitors. In
contrast, inactive, unphosphorylated MAPK or Akt was predomi-
nant in PD098059-treated or LY294002-treated Kuramochi cells
even in the presence of HGF. The level of active MAPK and Akt
was almost 20% and 10% of that in the HGF-stimulated control
(data not shown). The significant reduction in active MAPK by the
MEK inhibitor resulted in the suppression of constitutive motility
(59.9% of that in DMSO-treated cells) (Figure 5). However, the
stimulation of cell motility in response to HGF was retained in
PD098059-treated cells. In turn, PD098059 did not exhibit any
inhibitory effects on the constitutive invasiveness of Kuramochi
cells, but its stimulation in response to HGF was completely
abrogated. In contrast with PD098059, a PI3-kinase inhibitor,
LY294002 markedly inhibited the constitutive motility of
Kuramochi cells (14% of that in DMSO-treated control cells).
Again, stimulation of cell motility in response to HGF was exhib-
ited in LY294002-treated Kuramochi cells. None of the inhibitory
effects on constitutive invasiveness were shown by LY294002
treatment but the stimulation of invasiveness in response to HGF
was abrogated in LY294002-treated Kuramochi cells. The results
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Table 3 Motility assay
Cell line SKOV-3 Kuramochi MH KF
Control HGF (–) 135.2 ± 16.0 88.3 ± 36.8 51.5 ± 20.5 5.0 ± 2.9
HGF (+) 401.1 ± 83.3 391.2 ± 81.2 252.1 ± 129.3 65.3 ± 10.2
ras DN HGF (–) 97.5 ± 36.0 26.7 ± 7.9 5.7 ± 3.6 1.3 ± 0.9
(72.1%) (30.2%) (11.0%) (26.0%)
HGF (+) 223.3 ± 78.6 212.7 ± 20.0 151.8 ± 41.5 6.0 ± 3.3
(55.7%) (54.4%) (60.2%) (9.2%)
Control and ras DN represent cells infected with control virus AdCALacZ and dominant-negative Ras virus
AdexCAHRasY57 respectively. A total of 10 ng ml–1 of HGF were added into the lower compartment of the Boyden
chamber and cells were incubated for 10 h. The ratios of the migrated cell number compared to control virus-
infected cells are shown in parentheses.
Table 4 Invasion assay
Cell line SKOV-3 Kuramochi MH KF
Control HGF (–) 1346.0 ± 215.5 167.3 ± 25.7 170.0 ± 92.6 460.0 ± 76.5
HGF (+) 2323.8 ± 89.5 563.3 ± 153.1 604.3 ± 41.3 947.2 ± 170.3
ras DN HGF (–) 109.1 ± 13.7 26.0 ± 13.7 4.3 ± 2.6 3.7 ± 3.8
(8.1%) (15.6%) (2.5%) (0.7%)
HGF (+) 92.3 ± 18.7 43.0 ± 20.8 29.7 ± 16.2 28.0 ± 33.4
(4.0%) (7.6%) (4.9%) (3.0%)
A total of 10 ng/ml of HGF was added into the upper and lower compartments of the Boyden chamber, and
cells were incubated for 24 h. The ratios of the migrated cell number compared to control virus-infected cells
are shown in parentheses.suggested the implication of both MAPK and PI3-kinase pathways
in HGF-stimulated invasiveness of ovarian cancer cells. In
contrast, HGF-stimulated promotion of Kuramochi cell motility
was seemingly independent of the MAPK and PI3-kinase path-
ways.
DISCUSSION
The present study demonstrated the overexpression of HGFR in
ovarian cancer cells, although there was considerable variation in
the HGFR level among individual cell lines. Overexpressed
HGFR had the potential to promote its autophosphorylation
followed by MAPK activation in response to HGF. MAPK activa-
tion may be induced by activated Ras, indicating that the ovarian
cancer cell lines conserve the signalling pathway via Ras protein
as a downstream target of HGFR. In addition, we found no
evidence for the HGF-HGFR autocrine loop in these cells.
Concomitant with MAPK activation, HGF promoted the
motility of ovarian cancer cells. Cell motility was markedly
enhanced in the cell lines with relatively low constitutive motility.
In contrast, those cells with high constitutive motility were rela-
tively insensitive to HGF, suggesting that the constitutive motility
is the cumulative effect of signalling pathways unrelated to the
HGF-HGFR system. Activation of these signalling pathways in
the cells would mask the HGF-mediated stimulation of cell
motility. The stimulatory effect of HGF was blocked completely in
KF cells and partially in the remaining cells by the dominant-
negative Ras Y57 mutant protein. These results suggest that 
Ras-dependent signalling is a major route of HGF-mediated stim-
ulation of cell motility. However, Ras-independent signalling was
also involved, at least partially, in the motility activation of
ovarian cancer cells in response to HGF. Thus, the present findings
suggest that the induction of cell motility is a major aspect of the
action of HGF that is transmitted through the Ras-dependent
cascade in ovarian cancer cells. The ras mutations detected in
almost 30% of ovarian cancers would correspond to the constitu-
tive enhancement of signalling for cell motility.
The motility signal of HGF is transduced further downstream of
Ras. Ras is known to activate multiple signal transduction path-
ways, including the MAPK cascade, and PI3-kinase cascade. By
the use of a specific MEK inhibitor (PD098059) or a PI3-kinase
inhibitor (LY294002), we showed that seemingly neither the
MAPK nor the PI3-kinases pathway was essential to the HGF-
induced motility of Kuramochi cells. However, the stimulatory
effect of HGF exhibited by the dominant-negative Ras Y57-
infected Kuramochi cells indicates the presence of Ras-indepen-
dent signalling; an eightfold enhancement of cell motility was
shown in these cells. This Ras-independent signalling in response
to HGF would mask the inhibitory effect of PD098059 or
LY294002. As it has been shown that HGF activates MAPK and
PI3-kinase, and PI3-kinase in turn leads to activation of Rac
(Parker et al, 1995), further detailed studies are now required to
address whether the MAPK and PI3-kinase cascades are involved
in cell motility of ovarian cancer cells.
Another intriguing property of HGF in ovarian cancer cells is its
ability to promote invasion of the extracellular matrix. Similarly to
its effect on cell motility, HGF showed the potential to induce
invasion concomitant with MAPK activation, and expression of
dominant-negative Ras Y57 completely inhibited the HGF-
induced invasiveness of ovarian cancer cells. These observations
suggest that the HGF-HGFR-Ras signalling cascade is involved
importantly in the invasive phenotype shown by ovarian cancer
cells. As expected from the dominant-negative Ras Y57 infection,
both MEK and PI3-kinase inhibitors completely abrogated the
stimulation of invasiveness in response to HGF. These results are
compatible with the supposition that HGF-stimulated ovarian
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Figure 5 Effects of MEK inhibitor and Pl3-kinase inhibitor on cell motility and invasion. Kuramochi cells were plated in Boyden chambers in the presence of 10
mM PD098059 or 50 mM LY294002. Cells were treated with the same amount of carrier (DMSO) as the control. Motility and invasion were assayed as described
in Materials and Methods. Both PD098059 and LY294002 abrogated the HGF-stimulated invasiveness of Kuramochi cells, whereas their inhibitory effect on the
cell motility was not seencancer cell invasiveness requires the MAPK and PI3-kinase path-
ways downstream of Ras. Tumour cell invasion is the end result of
a complex series of steps. Cancer cells must move through the
extracellular matrix during invasion. Cell migration is considered
to be a key component of tumour cell invasion. However, the
extent of contribution of Ras-dependent signalling in response to
HGF is not identical between cell motility and invasiveness of
Kuramochi cells. HGF-HGFR signalling is coupled to the activa-
tion of proteases that mediate degradation of the extracellular
matrix-basement membrane, and play an impotent role in cellular
invasion and metastasis (Jeffer et al, 1996b). Thus, intensive
studies focusing on the interaction between the protease activation
and Ras-dependent signalling are now in progress.
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